Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase—a potential reason for resistance to Glivec in chronic myelogenous leukaemia-Reference-Cited by-同舟云学术

Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase—a potential reason for resistance to Glivec in chronic myelogenous leukaemia

Published:2003-11 Issue:10 Volume:66 Page:1879-1884
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Bakalova Rumiana,Ohba Hideki,Zhelev Zhivko,Ishikawa Mitsuru,Shinohara Yasuo,Baba Yoshinobu

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference21 articles.

1. Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification;Gorre;Science,2001

2. Bcr-Abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI-571: a prospective study;Von Bubnoff;Lancet,2002

3. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI-571 has a unique Bcr-Abl gene mutation;Hofmann;Blood,2002

4. High frequency of point mutations clustered within the adenosine triphosphate-binding region of Bcr/Abl in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance;Branford;Blood,2002

5. Glivec (STI-571, Imatinib), a rationally developed, targeted anticancer drug;Capdeville;Nature,2002

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interaction of the mTERT telomerase catalytic subunit with the c-Abl tyrosine kinase in mouse granulosa cells;Journal of Receptors and Signal Transduction;2020-03-04

2. Low Level of TERC Gene Amplification between Chronic Myeloid Leukaemia Patients Resistant and Respond to Imatinib Mesylate Treatment;Asian Pacific Journal of Cancer Prevention;2014-02-28

3. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells;Cancer Letters;2012-10

4. Telomerase: Basic and Clinical Approaches;Telomere Territory and Cancer;2012-08-14

5. hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications;Molecular Cancer Therapeutics;2011-03-01